Product Description
For moderate to severe pain after abdominal surgery (Sourced from: https://www.chictr.org.cn/showprojen.aspx?proj=135457)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: N/A
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Center for Clinical Pharmacology, the Third Xiangya Hospital, Central South University
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description

Countries in Clinic: China
Active Clinical Trial Count: 4
Highest Development Phases
Phase 3: Abdominal Pain|Pain Unspecified
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
CTR20212481 | P2 |
Completed |
Abdominal Pain |
2022-04-09 |
|
CTR20211452 | P1 |
Not yet recruiting |
Healthy Volunteers|Pain Unspecified |
None |
|
CTR20222714 | P3 |
Not yet recruiting |
Abdominal Pain |
None |
|
CTR20222580 | P3 |
Not yet recruiting |
Pain Unspecified |
None |